L8668
左乙拉西坦
≥98% (HPLC), powder, acetylcholine receptor inhibitor
别名:
(αS)-α-乙基-2-氧代-1-吡咯烷乙酰胺, 2（S）-（2-氧吡咯烷-1-基）丁酰胺
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C8H14N2O2
化学文摘社编号:
分子量:
170.21
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
产品名称
左乙拉西坦, ≥98% (HPLC)
assay
≥98% (HPLC)
form
powder
color
white
solubility
H2O: >5 mg/mL
originator
UCB Inc.
SMILES string
CC[C@H](N1CCCC1=O)C(N)=O
InChI
1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1
InChI key
HPHUVLMMVZITSG-LURJTMIESA-N
Gene Information
human ... CACNA1B(774), SV2A(9900)
General description
Levetiracetam is a member of the pyrrolidone family, which is a second-generation anti-epileptic drug (AED). It acts as a neuroprotective and hyperalgesic drug. Levetiracetam is implicated in cholinergic neurotransmission.
Application
Levetiracetam has been used as an anti-epileptic drug to study its effects on glucose-mediated death.
Biochem/physiol Actions
左乙拉西坦是一种具有抗癫痫活性的吡咯烷。
左乙拉西坦是一种具有抗癫痫活性的吡咯烷。左乙拉西坦的立体选择性结合仅限于中枢神经系统的突触质膜，而在周围组织中不发生立体选择性结合。左乙拉西坦在不影响正常神经元兴奋性的情况下抑制簇状放电，这表明它可以选择性地阻止癫痫样簇状放电的超同步和发作活动的传播。
Features and Benefits
This compound was developed by UCB Inc.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Still not finding the right product?
Explore all of our products under 左乙拉西坦
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves